vailsymposium

Dr. Michael Deininger received his MD from the University of Würzburg, Germany. He trained in Internal Medicine and Hematology/Oncology, followed by a PhD in leukemia biology at Imperial College, London. In 2002, he was recruited to Oregon Health & Science University. In 2010, he became Division Chief for Hematology and Hematologic Malignancies at the University of Utah, Senior Director for Transdisciplinary Research at Huntsman Cancer Institute, and M.M. Wintrobe Professor of Medicine. From 2021 to 2025, he served as Chief Scientific Officer of Versiti Inc. and Director of the Versiti Blood Research Institute, Milwaukee.

Deininger’s research spans the entire spectrum of myeloid malignancies, with a focus on translating basic discovery into clinical trials and ultimately clinical practice.  As a physician-scientist,  Deininger has led an NIH-funded lab for more than 20 years and served as PI on numerous clinical trials, including studies that led to the approval of new drugs to treat leukemia. He has published more than 300 peer-reviewed manuscripts.